Cargando…
Fresh from the biotech pipeline: fewer approvals, but biologics gain share
2022 saw a 25% drop in new drug approvals and a less predictable regulator.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838261/ https://www.ncbi.nlm.nih.gov/pubmed/36624153 http://dx.doi.org/10.1038/s41587-022-01630-6 |
| _version_ | 1784869244032253952 |
|---|---|
| author | Senior, Melanie |
| author_facet | Senior, Melanie |
| author_sort | Senior, Melanie |
| collection | PubMed |
| description | 2022 saw a 25% drop in new drug approvals and a less predictable regulator. |
| format | Online Article Text |
| id | pubmed-9838261 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98382612023-01-17 Fresh from the biotech pipeline: fewer approvals, but biologics gain share Senior, Melanie Nat Biotechnol News Feature 2022 saw a 25% drop in new drug approvals and a less predictable regulator. Nature Publishing Group US 2023-01-09 2023 /pmc/articles/PMC9838261/ /pubmed/36624153 http://dx.doi.org/10.1038/s41587-022-01630-6 Text en © The Author(s), under exclusive licence to Springer Nature America, Inc. 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | News Feature Senior, Melanie Fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| title | Fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| title_full | Fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| title_fullStr | Fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| title_full_unstemmed | Fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| title_short | Fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| title_sort | fresh from the biotech pipeline: fewer approvals, but biologics gain share |
| topic | News Feature |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838261/ https://www.ncbi.nlm.nih.gov/pubmed/36624153 http://dx.doi.org/10.1038/s41587-022-01630-6 |
| work_keys_str_mv | AT seniormelanie freshfromthebiotechpipelinefewerapprovalsbutbiologicsgainshare |